Exposure-response relationships and drug interactions of sirolimus

AAPS Journal

Volumn 6, Issue 4, 2004, Pages

  Zimmerman, James J ^a  

^a PFIZER INC   (United States)

Author keywords

Drug interactions; Exposure response relationship; Sirolimus

Indexed keywords

ACICLOVIR; ATORVASTATIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; ETHINYLESTRADIOL PLUS NORGESTREL; GLIBENCLAMIDE; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; RAPA; RAPAMYCIN; RAPMUNE; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; VERAPAMIL; VORICONAZOLE;

ACUTE GRAFT REJECTION; AGE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HLA MATCHING; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PROBABILITY; PROTEIN INDUCTION; RECIPIENT; SEX DIFFERENCE; VOLUNTEER; ADULT; BLOOD; CHILD; DRUG INTERACTION; FEMALE; GRAFT REJECTION; MALE; PRESCHOOL CHILD; STATISTICAL MODEL;

ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DRUG INTERACTIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; SIROLIMUS;

EID: 33644697765     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj060428     Document Type: Article

References (58)

1. Physicians' Desk Reference, 57th ed. Montvale. NJ: Medical Economics Company; 2004.
2. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Vonit. 1995;17:660-665.
3. United States Pharmacopeial Convention. USP Dictionary of USAN and International Drug Names. Rockville, MD: United States Pharmacopeial Convention.
4. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807-815.
5. Diasio RB, LoBuglio AF. Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed, New York. NY: McGraw-Hill; 1995:1291-1308.
6. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP 12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270:815-822.
7. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273:239-242.
8. Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci U S A. 1994;91:11477-11481.
9. Feuerstein N, Huang D, Prystowsky MB. Rapamycin selectively blocks interleukin-2 induced proliferating cell nuclear antigen gene expression in T lymphocyte. J Biol Chem. 1995;270:9454-9458.
10. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573.
11. Jefferies HBJ, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the "polyprimidine tract" mRNA family. Proc Natl Acad Sci U S A. 1994;91:4441-4445.
12. Zheng J, Sambol NC, Zimmerman J, Zaidi A. Population pharmacokinetics (PK) of sirolimus [abstract]. Clin Pharmacol Ther. 1996;59:150.
13. Van Buren CT. Sirolimus oral solution and tablets demonstrate equivalent safety and efficacy in renal allograft patients. Transplantation. 2000;69(suppl):S153-S154.
14. Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat rneal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol. 1999;39:1155-1161.
15. Pentikis H, Kriebel W, Reis P, Zimmerman JJ. The effect of ethnicity on the pharmacokinetics of sirolimus: a population pharmacokinetic analysis of phase 1 data [abstract]. AAPS Pharm Sci. 2003;5(S4):Abstract 2353.
16. Tejani A, Alexander S, Ettengger R, et al. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant. In press.
17. Shaw LM, Kaplan B, Brayman KL. Introduction and overview (Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus). Clin Ther. 2000;22(suppl B):B1-B13.
18. Jones K, Saadat-Lajevardi S, Lee T, et al. An immunoassay for the measurement of sirolimus. Clin Ther. 2000;22(suppl B):B49-B61.
19. Zimmerman JJ, Harper D, Getsy J, Jusko WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart. J Clin Pharmacol. 2003;43:1168-1176.
20. SAS Institute Inc. SAS/STAT, User's Guide, Version 8. Cary, NC: SAS Institute Inc; 2000.
21. Box GEP, Tidwell PW. Transformation of the independent variables. Technometrics. 1962;4:531-550.
22. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Disp. 1992;20:753-761.
23. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998;285:1104-1112.
24. 14C-Rapamucin (sirolimus) in healthy male subjects after a single oral dose [abstract]. ISSX Proc. 1997;12:26.
25. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res. 1998;15:1666-1672.
26. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735-7738.
27. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev. 1996;20:99-112.
28. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159-168.
29. Bottiger Y, Sawe J, Brattstrom C, et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther. 2001;69:32-40.
30. Floren LC, Christians U, Zimmerman JJ, et al. Sirolimus oral bioavailability increases eleven-fold with concomitant ketoconazole [abstract]. Clin Pharmacol Ther. 1999;65:159.
31. Patat A, Zimmerman JJ, Parks V, Richards J. Pharmacokinetic (PK) interaction study of sirolimus (SRL) and cyclosporine (CsA) [abstract]. Clin Pharmacol Ther. 2004;75:33.
32. Zimmerman JJ, Harper D, Speth JT, Fruncillo RJ, Getsy J, eds. Potential pharmacokinetic interactions between sirolimus and atorvastatin [abstract]. ESOT. 2001;(Oct 6-11):145.
33. Zimmerman JJ, Patat A, Souan J-L, Paty I, Cadieu G. Potential pharmacokinetic interactions between sirolimus and tacrolimus [abstract]. Am J Transplant. 2001;1(suppl 1):384.
34. Pichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos. 1990;18:711-719.
35. Pichard L, Fabre I, Fabre G, et al. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A Oxidase) in primary cultures of human hepatocytes and liver microsomes. Drug Metab Dispos. 1990;18:595-606.
36. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. Fed Europ Biochem Soc. 1993;324:99-102.
37. Emi Y, Tsunashima D, Ogawara K-I, Higaki K, Kimura T. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J Pharm Sci. 1998;87:295-299.
38. Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol. 1993;348:332-337.
39. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol. 1985;34:2533-2549.
40. Yusa K, Tsurua T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989;49:5002-5006.
41. Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol. 1992;43:2601-2608.
42. Kolars JC, Awni W, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338:1488-1490.
43. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, Wood AJJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999;3944-3948.
44. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080.
45. Hunt CM, Watkins PB, Saenger P, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther. 1992;51:18-23.
46. Larrey D, Funck-Brentano C, Breil P, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol. 1983;32:1063-1068.
47. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16:408-413.
48. Hofsli E, Nissen-Meyer J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer. 1989;44:149-154.
49. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica. 1995;25:261-270.
50. Siegmund MJ, Cardarelli C, Aksenriwevich I, Sugimoto Y, Pastan I, Gottesman MM. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cell. J Urol. 1994;151:485-491.
51. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992;90:1871-1878.
52. Westphal K, Weinbrenner A, Zschiesche M, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther. 2000;68:345-355.
53. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000;28:1369-1378.
54. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40:91-98.
55. De Lannoy IA, Silverman M. The MDR1 gene product, p-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun. 1992;189:51-557.
56. Brian WR, Sari M-A, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in saccharomyces cerevisiae. Biochemistry. 1990;29:11280-11292.
57. Guengerich FP, Brian WR, Iwasaki M, Sari M-A, Baarnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991;34:1838-1844.
58. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992;80:1528-1536.